A case report of ivabradine used for heart rate control of atrial fibrillation in acute decompensated heart failure.
Edward HardisonZachary L CoxKatherine HeckmanPatricia A KellyJoAnn LindenfeldPublished in: European heart journal. Case reports (2022)
current of cardiac pacemaker cells to slow heart rate (HR), and it currently carries a class IIa recommendation to reduce the risk of HF hospitalization and cardiac death in patients with left ventricular ejection fraction ≤35% and a symptomatic HR ≥70 b.p.m. Although current recommendations are for patients in sinus rhythm, ivabradine has a theoretical benefit in patients with AF given its mechanism of action. Because it does not negatively affect inotropy or blood pressure, ivabradine was used in our patient with a good clinical outcome. Our case provides an example of ivabradine's usefulness in patients with AF in RVR with a history of depressed systolic function.
Keyphrases
- heart rate
- ejection fraction
- blood pressure
- left ventricular
- heart failure
- atrial fibrillation
- aortic stenosis
- heart rate variability
- left atrial
- hypertrophic cardiomyopathy
- cardiac resynchronization therapy
- hypertensive patients
- liver failure
- oral anticoagulants
- acute myocardial infarction
- catheter ablation
- mitral valve
- case report
- direct oral anticoagulants
- end stage renal disease
- induced apoptosis
- oxidative stress
- prognostic factors
- respiratory failure
- left atrial appendage
- type diabetes
- peritoneal dialysis
- coronary artery disease
- acute coronary syndrome
- metabolic syndrome